Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Zynerba Pharmaceuticals, Inc. | zyne-20171231ex322956953.htm |
| 10-K - 10-K - Zynerba Pharmaceuticals, Inc. | zyne-20171231x10k.htm |
| EX-32.1 - EX-32.1 - Zynerba Pharmaceuticals, Inc. | zyne-20171231ex321e394f2.htm |
| EX-31.2 - EX-31.2 - Zynerba Pharmaceuticals, Inc. | zyne-20171231ex312b5e0c5.htm |
| EX-31.1 - EX-31.1 - Zynerba Pharmaceuticals, Inc. | zyne-20171231ex311184b2c.htm |
| EX-21.1 - EX-21.1 - Zynerba Pharmaceuticals, Inc. | zyne-20171231ex2115459e7.htm |
| EX-10.19 - EX-10.19 - Zynerba Pharmaceuticals, Inc. | zyne-20171231ex1019d97dc.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Zynerba Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statements on Form S-3 (Nos. 333-218638 and 333-213430) and Form S-8 (Nos. 333-216968, 333-216967, and 333-207973) of Zynerba Pharmaceuticals, Inc. of our report dated March 12, 2018, with respect to the consolidated balance sheets of Zynerba Pharmaceuticals, Inc. as of December 31, 2017 and 2016, and the related consolidated statements of operations, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements), which report appears in the December 31, 2017 annual report on Form 10-K of Zynerba Pharmaceuticals, Inc..
|
/s/ KPMG LLP |
|
Philadelphia, Pennsylvania |
|
March 12, 2018 |